To kick off National Mental Health Awareness Month, starting on May 1 the Child Mind Institute presents Speak Up for Kids, a month-long online dialogue to promote children’s mental health and help eliminate barriers to care. Responding to President Obama’s call for a national conversation about mental health in the wake of the tragedy in Newtown, Speak Up for Kids brings together the nation’s mental health leadership to give parents the information they need to remove stigma and get kids effective mental health care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61539-child-mind-institute-launches-speak-up-for-kids-online-programming
Potash Corporation of Saskatchewan Inc. (“PotashCorp”) today launched potashcorp-eKonomics.com, a new online resource that delivers easy-to-understand analyses of soil science data, agronomic information, research and best management practices to help farmers achieve greater financial success. As part of a larger campaign, the site aims to educate farmers about the benefits fertilizer – specifically potash – can deliver to their bottom line.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61611-potashcorp-launches-ekonomics-business-of-soil-fertility
To mark National Massage Therapy Awareness Week (NMTAW), October 20-26, the American Massage Therapy Association (AMTA) has compiled research that suggests symptoms of stress, anxiety and depression (all associated with mental health) may be alleviated with massage therapy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63936-amta-massage-therapy-research-roundup-mental-health-benefits
In support of American Diabetes Month®, Colgate Total kicked-off the “Small Steps Make a Big Difference” campaign to help raise awareness surrounding the often overlooked association between oral health and diabetes.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7332551-colgate-total-american-diabetes-association-small-steps-make-a-big-difference-campaign/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
HealthCare Partners, a division of DaVita Inc. (NYSE: DVA), a leading independent medical group in the United States, is encouraging Medicare beneficiaries to review their health care coverage during Medicare’s Open Enrollment Period.
From October 15 through December 7, Medicare holds its annual Open Enrollment Period. During this seven-week window, Medicare beneficiaries can make changes to their health and prescription drug plans for the following year.
If you are satisfied with your Medicare coverage, you may wonder how open enrollment applies to you. As the old adage goes, “if it isn’t broke, don’t fix it,” right?
While this may certainly be the case for many things in life, it may not be true about your Medicare coverage. Choosing a Medicare plan is similar to shopping for other insurance; by comparing different plans and rates, you choose the coverage that’s best for you.
To view the multimedia release go to:
http://www.multivu.com/players/English/7920151-healthcare-partners-medicare-open-enrollment/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
